The difference in transcriptomic profile between this HER2-poistive IBC population and that seen in the population in this trial with patients with TNBC and majority HR + IBC may reflect a difference in gene expression resulting from treatment with HER2-targeting therapies only versus treatment with chemotherapy. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.